Outcomes | CAZ-AVI sequencea | Ceftolozane/Tazobactam sequenceb |
---|---|---|
% of patients with cure | 93.04% | 91.52% |
% of patients died in hospital | 5.02% | 5.60% |
% of patients with AE | 6.12% | 7.48% |
Average number of days in hospital | 13.04 | 13.42 |
LYs | 4.411 | 4.384 |
QALYs | 4.021 | 3.982 |
Drug costs | € 2952 | € 2324 |
Hospitalisation costs | € 11,355 | € 11,781 |
SAE costs | € 185 | € 226 |
Recurrence costs | € 0 | € 0 |
Total costs | € 14,492 | € 14,331 |
Incremental cost per QALY gained | € 4099 |